Episode
Review Series on Myeloproliferative Neoplasms
- Podcast
- Blood Podcast
- Published
- Apr 2, 2026
- Duration seconds
- 1569
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/5cf8c948
Actions
POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/review-series-on-myeloproliferative-neoplasms/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-podcast-664776/review-series-on-myeloproliferative-neoplasms.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, Blood Associate Editor Dr. Jason Gotlib discusses the Review Series " The New Wave of Targeted Therapeutics for MPN’s ", with authors Drs. Stefan Constantinescu, Ann Mullally, and Marina Kremyanskaya. This Review Series covers 3 areas where exciting advances are occurring. Dr. Constantinescu discusses “ Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms ” which describes how new ways to switch off JAK signaling are delivering a suite of new small-molecule drugs with potential. Dr. Mullally discusses “ Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis ” which reviews the biology of calreticulin mutations in myelofibrosis and ET and how multiple different modalities can be brought to bear against this mutant surface protein, including monoclonal antibodies, bispecific T-cell engagers, and cellular and vaccine therapies. Dr. Kremyanskaya discusses “ Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis ” which outlines the major recent progress being made in controlling excessive erythropoiesis through pharmacological modulation of iron metabolism.